MAP’s vision to accelerate patient access to medicines, devices and diagnostics is at the heart of everything we do.
Our client has a long-term strategic relationship with us where we are paid to help with market access related challenges as they arise.
We were asked to explore whether their medicine should be excluded from the Payment by Results tariff to ensure that payment would be met centrally through NHS England budgets, rather than directly from tariff payments.
Using MAP Online and MAP Consulting expertise, we researched the current tariff related to the product.
We engaged with hospital KOLs to understand whether having the product included or excluded from tariff would have any impact on them.
Analysis of our findings led us to recommend that our client apply for exclusion from the tariff via the high cost drugs list, a process which we provided support for.
Our rapid turnaround and successful application to the high cost drugs list ensured smoother access for our client’s product.
Removal from the tariff was welcomed by clinicians who could now prescribe the product without the need to juggle competing priorities within the tariff.
Copyright © 2021.
MAP BioPharma Limited.
All rights reserved.
MAP BioPharma Limited
Upper Pendrill Court, Ermine Street North
Papworth Everard, Cambridge
Cambridgeshire, CB23 3UY
MAP BioPharma Limited is a registered company in England and Wales.
Company Registration Number 08209281
VAT Group Registration Number:
GB 292 8576 52